ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
Marc Kennis, May 1, 2023
ASX Life Sciences stocks are back, baby!
ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.
The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.
He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).
Stuart Roberts on AusBiz talking ASX Life Sciences stocks
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…